Clinical Trials Browser

Gastrointestinal Neoplasms × Cetuximab × Clear all

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT07020221 2026-03-09

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07404527 2026-02-13

Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery

Phase NA Recruiting

60 enrolled

Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Phase 3 Active not recruiting

831 enrolled 2 FDA

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT05039177 2025-02-11

HERKULES-3

Phase 1/2 Active not recruiting

102 enrolled

Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02675946 2022-01-26

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Phase 1 Unknown

72 enrolled

Gastrointestinal

Gastrointestinal Neoplasms

Clinical Trials

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

HERKULES-3

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)